SAGE Therapeutics Sees Unusually High Options Volume (SAGE)

SAGE Therapeutics Inc (NASDAQ:SAGE) saw unusually large options trading activity on Thursday. Traders purchased 2,163 put options on the company. This represents an increase of 1,323% compared to the typical daily volume of 152 put options.

Hedge funds have recently added to or reduced their stakes in the stock. Flinton Capital Management LLC increased its holdings in shares of SAGE Therapeutics by 1,900.0% in the 2nd quarter. Flinton Capital Management LLC now owns 680 shares of the biopharmaceutical company’s stock worth $106,000 after acquiring an additional 646 shares during the period. US Bancorp DE increased its holdings in shares of SAGE Therapeutics by 5,593.3% in the 2nd quarter. US Bancorp DE now owns 854 shares of the biopharmaceutical company’s stock worth $133,000 after acquiring an additional 839 shares during the period. Creative Planning acquired a new stake in shares of SAGE Therapeutics in the 2nd quarter worth about $210,000. Tiverton Asset Management LLC acquired a new stake in shares of SAGE Therapeutics in the 2nd quarter worth about $229,000. Finally, Opera Trading Capital acquired a new stake in shares of SAGE Therapeutics in the 3rd quarter worth about $233,000.

SAGE stock opened at $105.88 on Friday. SAGE Therapeutics has a fifty-two week low of $100.75 and a fifty-two week high of $195.97. The stock has a market capitalization of $5.09 billion, a P/E ratio of -14.93 and a beta of 2.72.

SAGE Therapeutics (NASDAQ:SAGE) last released its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported ($2.63) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($2.41) by ($0.22). During the same period last year, the business earned ($1.97) EPS. Analysts expect that SAGE Therapeutics will post -7.58 earnings per share for the current year.

SAGE has been the topic of a number of recent research reports. BidaskClub upgraded shares of SAGE Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 30th. Oppenheimer initiated coverage on shares of SAGE Therapeutics in a research report on Wednesday, October 10th. They issued a “buy” rating and a $170.00 price target on the stock. Morgan Stanley raised their price target on shares of SAGE Therapeutics from $228.00 to $230.00 and gave the stock an “overweight” rating in a research report on Thursday, October 11th. LADENBURG THALM/SH SH set a $235.00 price target on shares of SAGE Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, October 31st. Finally, Cowen restated a “buy” rating and issued a $207.00 price target on shares of SAGE Therapeutics in a research report on Thursday, November 1st. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $204.14.

TRADEMARK VIOLATION WARNING: “SAGE Therapeutics Sees Unusually High Options Volume (SAGE)” was published by WKRB News and is the property of of WKRB News. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.wkrb13.com/2018/12/07/sage-therapeutics-sees-unusually-high-options-volume-sage.html.

SAGE Therapeutics Company Profile

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

See Also: How Does the Quiet Period Work?

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply